Abstract:Background: Asthma is defined by the Global Initiative for Asthma (GINA) as a heterogeneous disease characterized by chronic airway inflammation. The pathogenesis of the disease is better understood with the comprehension of immunological pathways. These pathways differ by the type of recruited cells and released interleukin (IL). Thus, asthma can be classified into subtypes based on the underlying immune mechanism: eosinophilic asthma (EA) and non-eosinophilic asthma (NEA). Patients with EA tend to respond better to inhaled corticosteroid as compared to those with NEA. The distinction of EA is very important in the light of emergent type 2 inflammation targeted therapies. Methods: We performed a 1-year (2018) retrospective cohort analysis of the Nationwide Inpatient Database (NIS). We included all adult patients presenting with severe asthma. Patients were stratified into two groups: eosinophilic severe asthma and non-eosinophilic severe asthma. The primary outcomes measures were the prevalence of chronic steroid use, status asthmaticus, family history of asthma, food, drug and environmental allergies, presence of nasal polyps, allergic rhinitis, allergic dermatitis, need for mechanical ventilation, need for oxygen supplementation, gastroesophageal reflux disease, in-hospital mortality, and length of stay. We performed descriptive statistics. Continuous parametric variables were reported using a mean and standard deviation. Continuous nonparametric variables were reported using a median and interquartile range. To compare the characteristics of the two groups, we used the independent t-test for continuous parametric variables and the Mann-Whitney U test for continuous nonparametric variables. The Chi-square test was used to assess differences in categorical variables. Results: A total of 2,646 patients were included, out of which 882 belonged to the eosinophilic group and 1,764 were in the non-eosinophilic group. Comparing EA versus NEA, we have found that eosinophilic group was characterized by higher percentage of steroid use (18.3% vs. 9.5%, P < 0.001). This group also had higher rates of status asthmaticus and positive family history (P = 0.009 and 0.004, respectively). The presence of allergies, allergic rhinitis, nasal polyps, and allergic dermatitis was higher among patients with eosinophilia. The need for mechanical ventilation and supplemental oxygen was also higher among this group (P < 0.001 for both); however, there was no significant difference in mortality rate (P = 0.347) and the length of hospital stay was similar in both groups (P < 0.001). Conclusion: We showed herein that the eosinophilic subtype of asthma differs widely from the non-eosinophilic phenotype. Clinically, patients with eosinophilia might exhibit different symptomatology, more atopy, and concomitant comorbidities. However, this group might have better response to steroid therapy and might benefit from the new emergent T2 immune targeted therapy. The identification of EA is crucial for better disease control.

Severe Eosinophilic Asthma or Eosinophilic Granulomatosis with Polyangitis: potential biomarkers for novel diagnostic strategies

Serum Proteomic Analysis Identifies SAA1, FGA, SAP, and CETP as New Biomarkers for Eosinophilic Granulomatosis With Polyangiitis

SERPINA3, FGA, AGP1, ITIH3 and SAA1 as novel biomarkers for eosinophilic granulomatosis with polyangiitis diagnosis and activity assessment

Characteristics of Severe Asthma Clinic Patients with Eosinophilic Granulomatosis with Polyangiitis

Exploring novel perspectives on eosinophilic inflammation in severe asthma

Improving the diagnosis of eosinophilic asthma

The Determinants of Eosinophilia in Patients With Severe Asthma

Predictors of new-onset EGPA in patient with severe asthma treated with anti IL-4/13

How Can We Distinguish Them?

Biomarkers for a less invasive strategy to predict children with eosinophilic esophagitis

Biomarkers for severe eosinophilic asthma

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD

Diagnostic value of blood inflammatory and oxidative stress markers in severe allergic eosinophilic asthma patients undergoing anti-IL-5 therapy

Nonallergic Asthma and Its Severity: Biomarkers for Its Discrimination in Peripheral Samples

Biomarkers associated with disease severity in allergic and nonallergic asthma

Noninvasive biomarkers identify eosinophilic esophagitis: A prospective longitudinal study in children

International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis

Blood Eosinophil Count Is a Useful Biomarker to Identify Patients with Severe Eosinophilic Asthma

Clinical characteristics of eosinophilic granulomatosis with polyangiitis involving the lung in 13 patients

Eosinophilic granulomatosis with polyangiitis – Advances in pathogenesis, diagnosis, and treatment